A sthma is an enormous public health problem in the United States resulting in considerable symptom burden and cost. 1 The goal of asthma care is control of the disease; however, control requires collaborative work between patients and their clinicians. The role of the clinician is to provide a treatment plan that includes inhaled medications, recommendations for remediation of relevant environmental exposures, and ongoing assessment of asthma control. The role of the patient is to follow the treatment plan, which includes taking controller medications consistently and correctly, reducing relevant exposures, Background: The goals of asthma care are reductions in risk and impairment, but achieving these goals requires collaborative work between patients and their clinicians. The purpose of this study was to improve inhaled corticosteroid (ICS) adherence and asthma control by cueing therapeutic communication between patients with asthma and their primary care clinicians. Methods: We conducted a prospective, cluster-randomized, controlled effectiveness trial to assess the effect of providing visually standardized, interpreted peak fl ow graphs (CUE intervention) to patients and their clinicians on ICS adherence and asthma control. Asthma control outcomes were analyzed by season to account for seasonal variations in exacerbation frequency. Results: Although mean log-transformed ICS adherence was not signifi cantly different between the two groups, there was a trend toward preserved adherence in the intervention group over time ( P 5 .16). Intervention patients required fewer courses of oral steroids during winter (9% vs 23%, P , .001) and spring (3% and 17%, P , .001) compared with control subjects. Intervention patients also had fewer periods of worsening symptoms (65% vs 89%, P , .001) and fewer urgent care visits (10% vs 23%, P , .001) during winter compared with control subjects. Post hoc analysis showed signifi cant improvement in the intervention group with respect to ICS adherence during winter months ( P , .05), the likely explanation for the reduction in prednisone use and symptoms. Day-to-day peak fl ow variability in the intervention group fell consistently throughout the study from an average of 32% at baseline to 23% at fi nal measurement ( P , .001), indicating less airway reactivity over time. Conclusions: Our fi ndings provide evidence of the value of peak fl ow monitoring for patients with asthma during seasons of greatest vulnerability, the cold/fl u season. The peak fl ow information apparently led to improvements in ICS adherence resulting in less need for prednisone rescue and fewer episodes of worsening symptoms.